On analysis: these are short peptides and generally straightforward chromatographically, which means a poor purity result is more likely to reflect the synthesis than the method.
25 likes 11mo
Compounds · Secretagogues & GH axis · continued
Second pass at: Why this subcategory is stricter about sourcing than most posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Evidence quality in the secretagogue literature is honestly weaker than in the incretin literature. Large randomised controlled trials are rare. Most evidence is mechanistic or from small studies. This is why this subcategory has higher sourcing standards than most.
12 likes 11mo
stopper_shift, post #60: Injection-site reactions are reported more often in this family than for the incretins. Whether that is the compounds or the preparations they are typically supplied in is not established. That is the version I would defend. It is not the version I started with. Go to post
Grateful for the specificity. Vague answers to this question are what sent me looking.
Collapsed as off-topic by two members at trust level 3 or above
Reconstitution volumes in this family are often small enough that dead volume in the syringe is a meaningful fraction of the dose. A fixed-needle insulin syringe is worth the trouble here specifically.
A single observation, in a thread that deserves better than single observations.
Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within the period the supplier's own data covers is the conservative approach.
Marking that as an opinion rather than a finding.
7 likes 11mo
f.wojcik, post #57: The arithmetic in post #56 is right; the assumption feeding it is the part to check. Evidence quality in the secretagogue literature is honestly weaker than in the incretin literature. Large randomised controlled trials are rare. Most evidence is mechanistic or from small studies. This is why this subcategory has higher sourcing… Go to post
Post #65 describes the usual case. This is about the unusual one.
Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for.
That is the honest state of it as of this week.
Adding the measurement that post #67 says would settle it.
A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes identity confirmation genuinely useful here.
The reasoning is more useful than the number, which is why I have shown it.
0 likes 11mo
Post #67 put the caveat in the right place and I want to underline it.
Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for.
I would put a moderate confidence on that and no more.
0 likes 11mo
j.erdogan, post #27: Where I part company with post #23, and it is a narrow parting. Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within the period the supplier's own data covers is the conservative approach. Go to post
Building on post #67 rather than restating it.
Reconstitution volumes in this family are often small enough that dead volume in the syringe is a meaningful fraction of the dose. A fixed-needle insulin syringe is worth the trouble here specifically.
Posted with less confidence than the sentence structure implies.
Seconded. It reads as careful rather than confident, which is the right register.
0 likes 11mo
e.okafor, post #54: Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for. Go to post
Post #68 put the caveat in the right place and I want to underline it.
On analysis: these are short peptides and generally straightforward chromatographically, which means a poor purity result is more likely to reflect the synthesis than the method.
It is the kind of thing that is obvious once and never again.
np_gilmore, post #71: Seconded. It reads as careful rather than confident, which is the right register. Go to post
Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within the period the supplier's own data covers is the conservative approach.
The strength of my opinion here exceeds the strength of my evidence.
Injection-site reactions are reported more often in this family than for the incretins. Whether that is the compounds or the preparations they are typically supplied in is not established.
19 likes 11mo
Reconstitution volumes in this family are often small enough that dead volume in the syringe is a meaningful fraction of the dose. A fixed-needle insulin syringe is worth the trouble here specifically.
0 likes 11mo
g.pemberton_uk, post #67: Post #65 describes the usual case. This is about the unusual one. Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for. That is the honest state of it as of this week. Go to post
The arithmetic in post #74 is right; the assumption feeding it is the part to check.
On analysis: these are short peptides and generally straightforward chromatographically, which means a poor purity result is more likely to reflect the synthesis than the method.
That distinction has done more work for me than anything else in this category.
A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes identity confirmation genuinely useful here.
Caveat: everything above assumes the paperwork is what it says it is.
26 likes 11mo
Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for.
Nothing above should be read as advice about what anyone else should do.
19 likes 11mo
g.pemberton_uk, post #16: Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within the period the supplier's own data covers is the conservative approach. I have written this out at length because the short version keeps being misread. Go to post
This follows post #79 rather than contradicting it.
Injection-site reactions are reported more often in this family than for the incretins. Whether that is the compounds or the preparations they are typically supplied in is not established.
np_gilmore, post #71: Seconded. It reads as careful rather than confident, which is the right register. Go to post
Coming back to post #82, because the follow-up matters more than the original answer.
Reconstitution volumes in this family are often small enough that dead volume in the syringe is a meaningful fraction of the dose. A fixed-needle insulin syringe is worth the trouble here specifically.
Not the whole picture, but the part of it I can speak to.
A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes identity confirmation genuinely useful here.
That matches what I was told, which is not the same as knowing it.
0 likes 11mo
Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within the period the supplier's own data covers is the conservative approach.
Take it as a starting point and not as a specification.
17 likes 11mo
On analysis: these are short peptides and generally straightforward chromatographically, which means a poor purity result is more likely to reflect the synthesis than the method.
7 likes 11mo
ai.vukovic, post #66: Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within the period the supplier's own data covers is the conservative approach. Marking that as an opinion rather than a finding. Go to post
I read post #85 twice before replying, because I had assumed the opposite.
A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes identity confirmation genuinely useful here.
Post #85 answers the question as asked. The question underneath it is different.
Why this subcategory is stricter about sourcing than most: the evidence base is weaker and that is precisely why documentation quality matters more. A supplier page that clearly identifies the compound and the purity is more valuable for secretagogues than for incretin agonists where the evidence base is stronger.
Written in the hope of being told what I have missed.
0 likes 11mo
Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for.
I keep a log of this specifically because memory is unreliable about it.
0 likes 11mo
Thank you for taking the time. That was more work than a reply usually is.
23 likes 11mo